Payer / HTA meeting · Dr. Mariana Rossi

07 Sept 2026 · In person · Dr. Mariana Rossi, Royal Marsden · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0050—

Capture insight from this engagement

Location: Royal Marsden
Therapeutic area: Oncology
Country: United Kingdom
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Elderly / ECOG 2 patients
Comparator checkpoint monotherapy
Chemotherapy-free first line

Scientific content used

irAE management guide
VOYAGE-1 pivotal data summary

Questions raised

What is the evidence for re-challenge with checkpoint inhibitors after progression on vantrelimab?
Is there subgroup data for patients with untreated brain metastases?

Notes

Payer / HTA meeting with pathologist at Royal Marsden. Discussed elderly / ecog 2 patients, comparator checkpoint monotherapy, chemotherapy-free first line.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 5
Depth of exchange: 1
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0050

Audit history (0)

All create, update and approval events for this record

No audit events in sample data